JC
ABUS icon

JBF Capital’s Arbutus Biopharma ABUS Stock Holding History

JBF Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Hold
80,281
– – 0.05% 66
2026
Q1 		$361K Buy
+80,281
New +$351K 0.05% 76
2014
Q2 		– Sell
-60,410
Closed -$1.3M – 91
2014
Q1 		$1.3M Buy
+60,410
New +$1.09M 0.2% 30

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JBF Capital's ABUS Position: Q2 2026 in Review

JBF Capital held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 80,281 shares worth $385K. The position accounts for 0.05% of the portfolio, ranked #66.

JBF Capital first reported a position in ABUS in Q1 2014 and has held it in 3 quarters since. The position peaked at $1.3M in Q1 2014. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • JBF Capital held 80,281 shares of Arbutus Biopharma worth $385K as of Q2 2026.
  • JBF Capital left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up 0.05% of JBF Capital's portfolio in Q2 2026, its #66 holding.
  • JBF Capital first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 3 quarters since.
  • JBF Capital's Arbutus Biopharma position peaked at $1.3M in Q1 2014.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on JBF Capital's 13F filing for Q2 2026, filed 13 Aug 2026.